Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014, 55099-55103 [2013-21797]

Download as PDF Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices To submit comments: Send them to: By mail ......... Assistant Attorney General, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. Under Section 7003(d) of the Resource Conservation and Recovery Act (‘‘RCRA’’), a commenter may request an opportunity for a public meeting in the affected area. During the public comment period, the Consent Decree may be examined and downloaded at this Justice Department Web site: http:// www.usdoj.gov/enrd/Consent_ Decrees.html. We will provide a paper copy of the Consent Decree upon written request and payment of reproduction costs. Please mail your request and payment to: Consent Decree Library, U.S. DOJ—ENRD, P.O. Box 7611, Washington, DC 20044–7611. Please enclose a check or money order for $22.25 (25 cents per page reproduction cost) payable to the United States Treasury. For a paper copy without the appendices and signature pages, the cost is $16.00. Maureen M. Katz, Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division. [FR Doc. 2013–21850 Filed 9–6–13; 8:45 am] BILLING CODE 4410–15–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–378] Established Aggregate Production Quotas for Schedule I and II Controlled Substances and Established Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014 Drug Enforcement Administration (DEA), Department of Justice. ACTION: Notice. AGENCY: This notice establishes the initial 2014 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA) and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. DATES: Effective: September 9, 2013. FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy Evaluation and Analysis Section, Office of tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 15:01 Sep 06, 2013 Jkt 229001 Diversion Control, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 598–6812. SUPPLEMENTARY INFORMATION: Background Section 306 of the CSA (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. The 2014 aggregate production quotas and assessment of annual needs represent those quantities of Schedules I and II controlled substances and the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine to be manufactured in the United States in 2014 to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do not include imports of controlled substances for use in industrial processes. On July 3, 2013, a notice titled, ‘‘Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Proposed Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2014,’’ was published in the Federal Register (78 FR 40186). That notice proposed the 2014 aggregate production quotas for each basic class of controlled substance listed in Schedules I and II and the 2014 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. All interested persons were invited to comment on or object to the proposed aggregate production quotas and the proposed assessment of annual needs on or before August 2, 2013. Comments Received DEA received seven comments from DEA-registered manufacturers within the published comment period on a total of 23 Schedule I and II controlled substances and one List I chemical. Commenters stated that the proposed PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 55099 aggregate production quotas for (1Pentyl-1H-indol-3-yl)(2,2,3,3tetramethylcyclopropyl)methanone (UR144), [1-(5-fluoro-pentyl)-1H-indol-3yl](2,2,3,3tetramethylcyclopropyl)methanone (XLR11), N-(1-adamantyl)-1-pentyl-1Hindazole-3-carboxamide (AKB48), cathinone, amphetamine (for sale), codeine (for conversion), codeine (for sale), fentanyl, hydrocodone (for sale), hydromorphone, levomethorphan, methylphenidate, morphine (for conversion), morphine (for sale), noroxymorphone (for conversion), oripavine, oxycodone (for sale), oxymorphone (for conversion), oxymorphone (for sale), phenylacetone, tapentadol, tetrahydrocannabinol, and thebaine were insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. One commenter stated that the proposed assessment of annual needs quota for phenylpropanolamine (for conversion) was insufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, export requirements, and the establishment and maintenance of reserve stocks. Determination of 2014 Aggregate Production Quotas and Assessment of Annual Needs In determining the 2014 aggregate production quotas and assessment of annual needs, the DEA has taken into consideration the above comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 1315.11, in accordance with 21 U.S.C. 826(a), and other relevant factors, including the consideration of 2013 manufacturing quotas, current 2013 sales and inventories, 2014 export requirements, industrial use, additional applications for quotas, as well as information on research and product development requirements. Based on this information, the DEA has determined that adjustments to the proposed aggregate production quotas and assessment of annual needs for 1-[1-(2Thienyl)cyclohexyl]piperidine, carfentanil, cathinone, dihydromorphine, dimethyltryptamine, ecgonine, hydromorphone, levomethorphan, lysergic acid diethylamide, metazocine, methamphetamine, dmethamphetamine (for conversion), methyldesorphine, noroxymorphone (for conversion), oxymorphone (for conversion), phencyclidine, phenylacetone, ephedrine (for conversion), ephedrine (for sale), E:\FR\FM\09SEN1.SGM 09SEN1 55100 Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices phenylpropanolamine (for conversion), and pseudoephedrine (for sale) are warranted. This notice reflects those adjustments. Regarding (1-Pentyl-1H-indol-3yl)(2,2,3,3tetramethylcyclopropyl)methanone (UR144), [1-(5-fluoro-pentyl)-1H-indol-3yl](2,2,3,3tetramethylcyclopropyl)methanone (XLR11), N-(1-adamantyl)-1-pentyl-1Hindazole-3-carboxamide (AKB48), amphetamine (for sale), codeine (for conversion), codeine (for sale), fentanyl, hydrocodone (for sale), methylphenidate, morphine (for conversion), morphine (for sale), oripavine, oxycodone (for sale), oxymorphone (for sale), tapentadol, tetrahydrocannabinol, thebaine, and phenylpropanolamine (for sale), the DEA has determined that the proposed initial 2014 aggregate production quotas and assessment of annual needs are sufficient to meet the current 2014 estimated medical, scientific, research, and industrial needs of the United States. This notice finalizes these aggregate production quotas at the same amounts as proposed. DEA also specifically considered that inventory allowances granted to individual manufacturers may not always result in the availability of sufficient quantities to maintain an adequate reserve stock pursuant to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be concerning if a natural disaster or other unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need. As such, the DEA included in all Schedule II aggregate production quotas, and certain Schedule I aggregate production quotas, an additional 25% of the estimated medical, scientific, and research needs as part of the amount necessary to ensure the establishment and maintenance of reserve stocks. The established aggregate production quotas reflect these included amounts. This action will not affect the ability of manufacturers to maintain inventory allowances as specified by regulation. The DEA expects that maintaining this reserve in certain established aggregate production quotas will mitigate adverse public effects if an unforeseen event resulted in substantial disruption to the amount of controlled substances available to provide for legitimate public need, as determined by the DEA. The DEA does not anticipate utilizing the reserve in the absence of these circumstances. In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 1315.11, the Deputy Administrator hereby establishes the 2014 aggregate production quotas for the following Schedule I and II controlled substances and the 2014 assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Established 2014 Quotas (grams) tkelley on DSK3SPTVN1PROD with NOTICES Basic Class—Schedule I (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144) ............................................................................. [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ................................................................ 1-(1-Phenylcyclohexyl)pyrrolidine .................................................................................................................................................. 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ...................................................................................................................... 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) ..................................................................................................................... 1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................................. 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) ......................................................................................................... 1-Butyl-3-(1-naphthoyl)indole (JWH-073) ...................................................................................................................................... 1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-18 and RCS-8) ..................................................................................... 1-Hexyl-3-(1-naphthoyl)indole (JWH-019) ..................................................................................................................................... 1-Methyl-4-phenyl-4-propionoxypiperidine ..................................................................................................................................... 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678) ................................................................................................................ 1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203) ...................................................................................................................... 1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250) .................................................................................................................. 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398) ...................................................................................................................... 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) ..................................................................................................................... 1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4) .............................................................................................................. 1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081) ................................................................................................................. 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) ............................................................................................................. 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) ..................................................................................................................... 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) .................................................................................................................. 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) .................................................................................................................... 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) ................................................................................................................................. 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) .................................................................................................................. 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) ........................................................................................................................ 2,5-Dimethoxy-4-ethylamphetamine (DOET) ................................................................................................................................ 2,5-Dimethoxy-4-n-propylthiophenethylamine ............................................................................................................................... 2,5-Dimethoxyamphetamine .......................................................................................................................................................... 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2) .......................................................................................................... 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4) .................................................................................................... 3,4,5-Trimethoxyamphetamine ...................................................................................................................................................... 3,4-Methylenedioxyamphetamine (MDA) ...................................................................................................................................... 3,4-Methylenedioxymethamphetamine (MDMA) ........................................................................................................................... 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) ....................................................................................................................... 3,4-Methylenedioxy-N-methylcathinone (methylone) .................................................................................................................... 3,4-Methylenedioxypyrovalerone (MDPV) ..................................................................................................................................... 3-Methylfentanyl ............................................................................................................................................................................. 3-Methylthiofentanyl ....................................................................................................................................................................... 4-Bromo-2,5-dimethoxyamphetamine (DOB) ................................................................................................................................ 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) ............................................................................................................................ 4-Methoxyamphetamine ................................................................................................................................................................ 4-Methyl-2,5-dimethoxyamphetamine (DOM) ................................................................................................................................ 4-Methylaminorex .......................................................................................................................................................................... VerDate Mar<15>2010 15:01 Sep 06, 2013 Jkt 229001 PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 E:\FR\FM\09SEN1.SGM 09SEN1 15 15 10 45 45 15 45 45 45 45 2 45 45 45 45 45 45 45 30 30 30 30 30 30 30 25 25 25 30 30 25 55 50 40 50 35 2 2 25 25 100 25 25 Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices Established 2014 Quotas (grams) tkelley on DSK3SPTVN1PROD with NOTICES Basic Class—Schedule I 4-Methyl-N-methylcathinone (mephedrone) .................................................................................................................................. 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol ................................................................................................... 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP-47, 497 C8-homolog) .................... 5-Methoxy-3,4-methylenedioxyamphetamine ................................................................................................................................ 5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................................ 5-Methoxy-N,N-dimethyltryptamine ............................................................................................................................................... Acetyl-alpha-methylfentanyl ........................................................................................................................................................... Acetyldihydrocodeine ..................................................................................................................................................................... Acetylmethadol .............................................................................................................................................................................. Allylprodine .................................................................................................................................................................................... Alphacetylmethadol ........................................................................................................................................................................ Alpha-ethyltryptamine .................................................................................................................................................................... Alphameprodine ............................................................................................................................................................................. Alphamethadol ............................................................................................................................................................................... Alpha-methylfentanyl ..................................................................................................................................................................... Alpha-methylthiofentanyl ................................................................................................................................................................ Alpha-methyltryptamine (AMT) ...................................................................................................................................................... Aminorex ........................................................................................................................................................................................ Benzylmorphine ............................................................................................................................................................................. Betacetylmethadol ......................................................................................................................................................................... Beta-hydroxy-3-methylfentanyl ...................................................................................................................................................... Beta-hydroxyfentanyl ..................................................................................................................................................................... Betameprodine ............................................................................................................................................................................... Betaprodine .................................................................................................................................................................................... Bufotenine ...................................................................................................................................................................................... Cathinone ....................................................................................................................................................................................... Codeine Methylbromide ................................................................................................................................................................. Codeine-N-oxide ............................................................................................................................................................................ Desomorphine ................................................................................................................................................................................ Diethyltryptamine ........................................................................................................................................................................... Difenoxin ........................................................................................................................................................................................ Dihydromorphine ............................................................................................................................................................................ Dimethyltryptamine ........................................................................................................................................................................ Dipipanone ..................................................................................................................................................................................... Fenethylline .................................................................................................................................................................................... Gamma-hydroxybutyric acid .......................................................................................................................................................... Heroin ............................................................................................................................................................................................ Hydromorphinol .............................................................................................................................................................................. Hydroxypethidine ........................................................................................................................................................................... Ibogaine ......................................................................................................................................................................................... Lysergic acid diethylamide (LSD) .................................................................................................................................................. Marihuana ...................................................................................................................................................................................... Mescaline ....................................................................................................................................................................................... Methaqualone ................................................................................................................................................................................ Methcathinone ............................................................................................................................................................................... Methyldesorphine ........................................................................................................................................................................... Methyldihydromorphine .................................................................................................................................................................. Morphine Methylbromide ............................................................................................................................................................... Morphine Methylsulfonate .............................................................................................................................................................. Morphine-N-oxide .......................................................................................................................................................................... N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) ................................................................................................... N-Benzylpiperazine ........................................................................................................................................................................ N,N-Dimethylamphetamine ............................................................................................................................................................ N-Ethyl-1-phenylcyclohexylamine .................................................................................................................................................. N-Ethylamphetamine ..................................................................................................................................................................... N-Hydroxy-3,4-methylenedioxyamphetamine ................................................................................................................................ Noracymethadol ............................................................................................................................................................................. Norlevorphanol ............................................................................................................................................................................... Normethadone ............................................................................................................................................................................... Normorphine .................................................................................................................................................................................. Para-fluorofentanyl ......................................................................................................................................................................... Parahexyl ....................................................................................................................................................................................... Phenomorphan .............................................................................................................................................................................. Pholcodine ..................................................................................................................................................................................... Properidine ..................................................................................................................................................................................... Psilocybin ....................................................................................................................................................................................... Psilocyn .......................................................................................................................................................................................... Tetrahydrocannabinols .................................................................................................................................................................. Thiofentanyl ................................................................................................................................................................................... Tilidine ............................................................................................................................................................................................ Trimeperidine ................................................................................................................................................................................. VerDate Mar<15>2010 15:01 Sep 06, 2013 Jkt 229001 PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 55101 E:\FR\FM\09SEN1.SGM 09SEN1 45 68 53 25 25 25 2 2 2 2 2 25 2 2 2 2 25 25 2 2 2 2 2 2 3 70 5 200 5 25 50 3,990,000 35 5 5 70,250,000 25 2 2 5 35 21,000 25 10 25 2 2 5 5 175 15 25 25 5 24 24 2 52 2 18 2 5 2 2 2 30 30 491,000 2 10 2 55102 Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices Established 2014 Quotas (grams) Basic Class—Schedule II 1-Phenylcyclohexylamine .............................................................................................................................................................. 1-Piperdinocyclohexanecarbonitrile (PCC) .................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ................................................................................................................................... Alfentanil ........................................................................................................................................................................................ Alphaprodine .................................................................................................................................................................................. Amobarbital .................................................................................................................................................................................... Amphetamine (for conversion) ...................................................................................................................................................... Amphetamine (for sale) ................................................................................................................................................................. Carfentanil ...................................................................................................................................................................................... Cocaine .......................................................................................................................................................................................... Codeine (for conversion) ............................................................................................................................................................... Codeine (for sale) .......................................................................................................................................................................... Dextropropoxyphene ...................................................................................................................................................................... Dihydrocodeine .............................................................................................................................................................................. Diphenoxylate ................................................................................................................................................................................ Ecgonine ........................................................................................................................................................................................ Ethylmorphine ................................................................................................................................................................................ Fentanyl ......................................................................................................................................................................................... Glutethimide ................................................................................................................................................................................... Hydrocodone (for sale) .................................................................................................................................................................. Hydromorphone ............................................................................................................................................................................. Isomethadone ................................................................................................................................................................................ Levo-alphacetylmethadol (LAAM) .................................................................................................................................................. Levomethorphan ............................................................................................................................................................................ Levorphanol ................................................................................................................................................................................... Lisdexamfetamine .......................................................................................................................................................................... Meperidine ..................................................................................................................................................................................... Meperidine Intermediate-A ............................................................................................................................................................ Meperidine Intermediate-B ............................................................................................................................................................ Meperidine Intermediate-C ............................................................................................................................................................ Metazocine ..................................................................................................................................................................................... Methadone (for sale) ..................................................................................................................................................................... Methadone Intermediate ................................................................................................................................................................ Methamphetamine ......................................................................................................................................................................... 3 3 2,687,500 17,625 3 9 18,375,000 49,000,000 19 240,000 68,750,000 46,125,000 19 100,750 750,000 144,000 3 2,108,750 3 99,625,000 6,750,000 5 4 195 2,000 23,750,000 6,250,000 6 11 6 19 31,875,000 38,875,000 2,811,375 [1,250,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 1,500,000 grams for methamphetamine mostly for conversion to a schedule III product; and 61,375 grams for methamphetamine (for sale)] Methylphenidate ............................................................................................................................................................................. Morphine (for conversion) .............................................................................................................................................................. Morphine (for sale) ........................................................................................................................................................................ Nabilone ......................................................................................................................................................................................... Noroxymorphone (for conversion) ................................................................................................................................................. Noroxymorphone (for sale) ............................................................................................................................................................ Opium (powder) ............................................................................................................................................................................. Opium (tincture) ............................................................................................................................................................................. Oripavine ........................................................................................................................................................................................ Oxycodone (for conversion) .......................................................................................................................................................... Oxycodone (for sale) ..................................................................................................................................................................... Oxymorphone (for conversion) ...................................................................................................................................................... Oxymorphone (for sale) ................................................................................................................................................................. Pentobarbital .................................................................................................................................................................................. Phenazocine .................................................................................................................................................................................. Phencyclidine ................................................................................................................................................................................. Phenmetrazine ............................................................................................................................................................................... Phenylacetone ............................................................................................................................................................................... Racemethorphan ........................................................................................................................................................................... Remifentanil ................................................................................................................................................................................... Secobarbital ................................................................................................................................................................................... Sufentanil ....................................................................................................................................................................................... Tapentadol ..................................................................................................................................................................................... Thebaine ........................................................................................................................................................................................ Proposed 2014 Quotas tkelley on DSK3SPTVN1PROD with NOTICES Basic Class—List I Chemicals Ephedrine (for conversion) ............................................................................................................................................................ Ephedrine (for sale) ....................................................................................................................................................................... Phenylpropanolamine (for conversion) .......................................................................................................................................... Phenylpropanolamine (for sale) ..................................................................................................................................................... Pseudoephedrine (for conversion) ................................................................................................................................................ Pseudoephedrine (for sale) ........................................................................................................................................................... VerDate Mar<15>2010 15:01 Sep 06, 2013 Jkt 229001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 96,750,000 91,250,000 62,500,000 30,375 17,500,000 1,462,500 112,500 625,000 22,750,000 9,250,000 149,375,000 25,000,000 7,750,000 35,000,000 6 19 3 67,000,000 3 3,750 215,003 6,255 17,500,000 145,000,000 E:\FR\FM\09SEN1.SGM 09SEN1 1,000,000 3,000,000 44,800,000 5,300,000 5,000 192,000,000 Federal Register / Vol. 78, No. 174 / Monday, September 9, 2013 / Notices The Deputy Administrator also establishes aggregate production quotas for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 at zero. Pursuant to 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Deputy Administrator may adjust the 2014 aggregate production quotas and assessment of annual needs as needed. Dated: August 30, 2013. Thomas M. Harrigan, Deputy Administrator. [FR Doc. 2013–21797 Filed 9–6–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Employee Benefits Security Administration [Application No. D–11758] Notice of Proposed Exemption involving AT&T Inc. (Together With AT&T Inc.’s Affiliates, AT&T or the Applicant) Located in Dallas, TX Employee Benefits Security Administration, U.S. Department of Labor. ACTION: Notice of Proposed Exemption. AGENCY: This document contains a notice of pendency before the Department of Labor (the Department) of a proposed individual exemption from certain prohibited transaction restrictions of the Employee Retirement Income Security Act of 1974, as amended (ERISA or the Act), and the Internal Revenue Code of 1986, as amended (the Code). The proposed transactions involve AT&T, the AT&T Pension Benefit Plan (the Plan), and the SBC Master Pension Trust (the Trust). The proposed exemption, if granted, would affect the Plan and its participants and beneficiaries. Effective Date: If granted, this proposed exemption will be effective as of September 1, 2013. DATES: Written comments and requests for a public hearing on the proposed exemption should be submitted to the Department within 55 days from the date of publication of this Federal Register Notice. ADDRESSES: Comments and requests for a hearing should state: (1) The name, address, and telephone number of the person making the comment or request, and (2) the nature of the person’s interest in the proposed exemption and the manner in which the person would be adversely affected by the exemption, if granted. A request for a hearing must also state the issues to be addressed and tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 15:01 Sep 06, 2013 Jkt 229001 include a general description of the evidence to be presented at the hearing. All written comments and requests for a public hearing concerning the proposed exemption should be sent to the Office of Exemption Determinations, Employee Benefits Security Administration, Room N–5700, U.S. Department of Labor, 200 Constitution Avenue NW., Washington DC 20210, Attention: Application No. D–11758. Interested persons are also invited to submit comments and/or hearing requests to EBSA via email or FAX. Any such comments or requests should be sent either by email to: moffitt.betty@ dol.gov, or by FAX to (202) 219–0204 by the end of the scheduled comment period. The application for exemption and the comments received will be available for public inspection in the Public Documents Room of the Employee Benefits Security Administration, U.S. Department of Labor, Room N–1513, 200 Constitution Avenue NW., Washington, DC 20210. Comments and hearing requests will also be available online at www.regulations.gov and www.dol.gov/ ebsa, at no charge. Warning: If you submit written comments or hearing requests, do not include any personally identifiable information (such as name, address, or other contact information) or confidential business information that you do not want publicly disclosed. All comments and hearing requests may be posted on the Internet and can be retrieved by most Internet search engines. FOR FURTHER INFORMATION CONTACT: Anna Mpras Vaughan, Office of Exemption Determinations, Employee Benefits Security Administration, U.S. Department of Labor, telephone (202) 693–8565. (This is not a toll-free number.) SUPPLEMENTARY INFORMATION: This document contains a notice of proposed exemption that, if granted, would provide exemptive relief from sections 406(a)(1)(A), 406(a)(1)(B), 406(a)(1)(D), 406(a)(1)(E), 406(a)(2), 406(b)(1), 406(b)(2), and 407(a) of the Act and the sanctions resulting from the application of section 4975 of the Code, by reason of section 4975(c)(1)(A), 4975(c)(1)(B), 4975(c)(1)(D) and 4975(c)(1)(E) of the Code. The proposed exemption has been requested by AT&T pursuant to section 408(a) of the Act and section 4975(c)(2) of the Code, and in accordance with the procedures set forth in 29 CFR Part 2570, Subpart B (76 FR 66637, 66644, October 27, 2011). Effective December 31, 1978, section 102 of the Reorganization Plan No. 4 of 1978, 5 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 55103 U.S.C. App. 1 (1996), transferred the authority of the Secretary of the Treasury to issue administrative exemptions under section 4975(c)(2) of the Code to the Secretary of Labor. Accordingly, this notice of proposed exemption is being issued solely by the Department. Summary of Facts and Representations 1 Background 1. AT&T Inc. (together with its affiliates, AT&T), formerly known as SBC Communications Inc., is a holding company incorporated in 1983 under the laws of the State of Delaware that has its principal executive offices in Dallas, Texas. AT&T, a provider of telecommunications services, offers its services and products to consumers in the U.S. and to businesses and other providers of telecommunications services worldwide. The services and products that AT&T offers vary by market, and include: wireless communications, local exchange services, long-distance services, data/ broadband and Internet services, video services, telecommunications equipment, managed networking and wholesale services. 2. AT&T is the sponsor of the AT&T Pension Benefit Plan (the Plan). Effective December 14, 2010, the Plan was amended (the 2010 Amendment) to name the Plan’s named fiduciary, AT&T Services, as the plan administrator. AT&T Services, pursuant to delegation (the Delegation) from its Board of Directors (the Board) dated July 1, 2011, delegated to the AT&T Inc. Benefit Plan Investment Committee (the Committee) all powers and authority that may be necessary or appropriate to the establishment, qualification, administration, maintenance, and operation of the SBC Master Pension Trust (the Trust) established as part of the Plan. Notwithstanding its power to delegate authority, the Committee retains, and may not delegate, the authority to authorize ‘‘companydirected’’ investments (i.e., investments that have not been delegated to a third party investment manager) in amounts greater than $200,000,000. 3. In addition to AT&T Services and the Committee, other Plan fiduciaries include Brock Fiduciary Services LLC (the Independent Fiduciary), an investment manager that is independent of AT&T Inc. 1 The Summary of Facts and Representations is based on the Applicant’s representations and does not reflect the views of the Department. E:\FR\FM\09SEN1.SGM 09SEN1

Agencies

[Federal Register Volume 78, Number 174 (Monday, September 9, 2013)]
[Notices]
[Pages 55099-55103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-21797]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-378]


Established Aggregate Production Quotas for Schedule I and II 
Controlled Substances and Established Assessment of Annual Needs for 
the List I Chemicals Ephedrine, Pseudoephedrine, and 
Phenylpropanolamine for 2014

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice establishes the initial 2014 aggregate production 
quotas for controlled substances in Schedules I and II of the 
Controlled Substances Act (CSA) and assessment of annual needs for the 
List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: Effective: September 9, 2013.

FOR FURTHER INFORMATION CONTACT: Ruth A. Carter, Chief, Policy 
Evaluation and Analysis Section, Office of Diversion Control, Drug 
Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 
22152, Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Background

    Section 306 of the CSA (21 U.S.C. 826) requires the Attorney 
General to establish aggregate production quotas for each basic class 
of controlled substance listed in Schedules I and II and for the List I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. This 
responsibility has been delegated to the Administrator of the DEA by 28 
CFR 0.100. The Administrator, in turn, has redelegated this function to 
the Deputy Administrator, pursuant to 28 CFR 0.104.
    The 2014 aggregate production quotas and assessment of annual needs 
represent those quantities of Schedules I and II controlled substances 
and the List I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine to be manufactured in the United States in 2014 to 
provide for the estimated medical, scientific, research, and industrial 
needs of the United States, lawful export requirements, and the 
establishment and maintenance of reserve stocks. These quotas include 
imports of ephedrine, pseudoephedrine, and phenylpropanolamine but do 
not include imports of controlled substances for use in industrial 
processes.
    On July 3, 2013, a notice titled, ``Proposed Aggregate Production 
Quotas for Schedule I and II Controlled Substances and Proposed 
Assessment of Annual Needs for the List I Chemicals Ephedrine, 
Pseudoephedrine, and Phenylpropanolamine for 2014,'' was published in 
the Federal Register (78 FR 40186). That notice proposed the 2014 
aggregate production quotas for each basic class of controlled 
substance listed in Schedules I and II and the 2014 assessment of 
annual needs for the List I chemicals ephedrine, pseudoephedrine, and 
phenylpropanolamine. All interested persons were invited to comment on 
or object to the proposed aggregate production quotas and the proposed 
assessment of annual needs on or before August 2, 2013.

Comments Received

    DEA received seven comments from DEA-registered manufacturers 
within the published comment period on a total of 23 Schedule I and II 
controlled substances and one List I chemical. Commenters stated that 
the proposed aggregate production quotas for (1-Pentyl-1H-indol-3-
yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-
pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 
(XLR11), N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), 
cathinone, amphetamine (for sale), codeine (for conversion), codeine 
(for sale), fentanyl, hydrocodone (for sale), hydromorphone, 
levomethorphan, methylphenidate, morphine (for conversion), morphine 
(for sale), noroxymorphone (for conversion), oripavine, oxycodone (for 
sale), oxymorphone (for conversion), oxymorphone (for sale), 
phenylacetone, tapentadol, tetrahydrocannabinol, and thebaine were 
insufficient to provide for the estimated medical, scientific, 
research, and industrial needs of the United States, export 
requirements, and the establishment and maintenance of reserve stocks. 
One commenter stated that the proposed assessment of annual needs quota 
for phenylpropanolamine (for conversion) was insufficient to provide 
for the estimated medical, scientific, research, and industrial needs 
of the United States, export requirements, and the establishment and 
maintenance of reserve stocks.

Determination of 2014 Aggregate Production Quotas and Assessment of 
Annual Needs

    In determining the 2014 aggregate production quotas and assessment 
of annual needs, the DEA has taken into consideration the above 
comments along with the factors set forth at 21 CFR 1303.11 and 21 CFR 
1315.11, in accordance with 21 U.S.C. 826(a), and other relevant 
factors, including the consideration of 2013 manufacturing quotas, 
current 2013 sales and inventories, 2014 export requirements, 
industrial use, additional applications for quotas, as well as 
information on research and product development requirements. Based on 
this information, the DEA has determined that adjustments to the 
proposed aggregate production quotas and assessment of annual needs for 
1-[1-(2-Thienyl)cyclohexyl]piperidine, carfentanil, cathinone, 
dihydromorphine, dimethyltryptamine, ecgonine, hydromorphone, 
levomethorphan, lysergic acid diethylamide, metazocine, 
methamphetamine, d-methamphetamine (for conversion), methyldesorphine, 
noroxymorphone (for conversion), oxymorphone (for conversion), 
phencyclidine, phenylacetone, ephedrine (for conversion), ephedrine 
(for sale),

[[Page 55100]]

phenylpropanolamine (for conversion), and pseudoephedrine (for sale) 
are warranted. This notice reflects those adjustments.
    Regarding (1-Pentyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone (UR-144), [1-(5-fluoro-pentyl)-1H-
indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11), N-(1-
adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48), amphetamine (for 
sale), codeine (for conversion), codeine (for sale), fentanyl, 
hydrocodone (for sale), methylphenidate, morphine (for conversion), 
morphine (for sale), oripavine, oxycodone (for sale), oxymorphone (for 
sale), tapentadol, tetrahydrocannabinol, thebaine, and 
phenylpropanolamine (for sale), the DEA has determined that the 
proposed initial 2014 aggregate production quotas and assessment of 
annual needs are sufficient to meet the current 2014 estimated medical, 
scientific, research, and industrial needs of the United States. This 
notice finalizes these aggregate production quotas at the same amounts 
as proposed.
    DEA also specifically considered that inventory allowances granted 
to individual manufacturers may not always result in the availability 
of sufficient quantities to maintain an adequate reserve stock pursuant 
to 21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be 
concerning if a natural disaster or other unforeseen event resulted in 
substantial disruption to the amount of controlled substances available 
to provide for legitimate public need. As such, the DEA included in all 
Schedule II aggregate production quotas, and certain Schedule I 
aggregate production quotas, an additional 25% of the estimated 
medical, scientific, and research needs as part of the amount necessary 
to ensure the establishment and maintenance of reserve stocks. The 
established aggregate production quotas reflect these included amounts. 
This action will not affect the ability of manufacturers to maintain 
inventory allowances as specified by regulation. The DEA expects that 
maintaining this reserve in certain established aggregate production 
quotas will mitigate adverse public effects if an unforeseen event 
resulted in substantial disruption to the amount of controlled 
substances available to provide for legitimate public need, as 
determined by the DEA. The DEA does not anticipate utilizing the 
reserve in the absence of these circumstances.
    In accordance with 21 U.S.C. 826, 21 CFR 1303.11, and 21 CFR 
1315.11, the Deputy Administrator hereby establishes the 2014 aggregate 
production quotas for the following Schedule I and II controlled 
substances and the 2014 assessment of annual needs for the List I 
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 
expressed in grams of anhydrous acid or base, as follows:

------------------------------------------------------------------------
                                                        Established 2014
               Basic Class--Schedule I                   Quotas (grams)
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-                                     15
 tetramethylcyclopropyl)methanone (UR-144)...........
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-                          15
 tetramethylcyclopropyl)methanone (XLR11)............
1-(1-Phenylcyclohexyl)pyrrolidine....................                 10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)....                 45
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)...                 45
1-[1-(2-Thienyl)cyclohexyl]piperidine................                 15
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-                45
 200)................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)..............                 45
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR-                45
 18 and RCS-8).......................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)..............                 45
1-Methyl-4-phenyl-4-propionoxypiperidine.............                  2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678)...                 45
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)....                 45
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250)...                 45
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)....                 45
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)....                 45
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4)                 45
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)..                 45
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)                 30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E).....                 30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)....                 30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)....                 30
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).............                 30
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)....                 30
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)......                 30
2,5-Dimethoxy-4-ethylamphetamine (DOET)..............                 25
2,5-Dimethoxy-4-n-propylthiophenethylamine...........                 25
2,5-Dimethoxyamphetamine.............................                 25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-                30
 2)..................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine                   30
 (2C-T-4)............................................
3,4,5-Trimethoxyamphetamine..........................                 25
3,4-Methylenedioxyamphetamine (MDA)..................                 55
3,4-Methylenedioxymethamphetamine (MDMA).............                 50
3,4-Methylenedioxy-N-ethylamphetamine (MDEA).........                 40
3,4-Methylenedioxy-N-methylcathinone (methylone).....                 50
3,4-Methylenedioxypyrovalerone (MDPV)................                 35
3-Methylfentanyl.....................................                  2
3-Methylthiofentanyl.................................                  2
4-Bromo-2,5-dimethoxyamphetamine (DOB)...............                 25
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)...........                 25
4-Methoxyamphetamine.................................                100
4-Methyl-2,5-dimethoxyamphetamine (DOM)..............                 25
4-Methylaminorex.....................................                 25

[[Page 55101]]

 
4-Methyl-N-methylcathinone (mephedrone)..............                 45
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-                                  68
 hydroxycyclohexyl]-phenol...........................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-                53
 phenol (cannabicyclohexanol or CP-47, 497 C8-
 homolog)............................................
5-Methoxy-3,4-methylenedioxyamphetamine..............                 25
5-Methoxy-N,N-diisopropyltryptamine..................                 25
5-Methoxy-N,N-dimethyltryptamine.....................                 25
Acetyl-alpha-methylfentanyl..........................                  2
Acetyldihydrocodeine.................................                  2
Acetylmethadol.......................................                  2
Allylprodine.........................................                  2
Alphacetylmethadol...................................                  2
Alpha-ethyltryptamine................................                 25
Alphameprodine.......................................                  2
Alphamethadol........................................                  2
Alpha-methylfentanyl.................................                  2
Alpha-methylthiofentanyl.............................                  2
Alpha-methyltryptamine (AMT).........................                 25
Aminorex.............................................                 25
Benzylmorphine.......................................                  2
Betacetylmethadol....................................                  2
Beta-hydroxy-3-methylfentanyl........................                  2
Beta-hydroxyfentanyl.................................                  2
Betameprodine........................................                  2
Betaprodine..........................................                  2
Bufotenine...........................................                  3
Cathinone............................................                 70
Codeine Methylbromide................................                  5
Codeine-N-oxide......................................                200
Desomorphine.........................................                  5
Diethyltryptamine....................................                 25
Difenoxin............................................                 50
Dihydromorphine......................................          3,990,000
Dimethyltryptamine...................................                 35
Dipipanone...........................................                  5
Fenethylline.........................................                  5
Gamma-hydroxybutyric acid............................         70,250,000
Heroin...............................................                 25
Hydromorphinol.......................................                  2
Hydroxypethidine.....................................                  2
Ibogaine.............................................                  5
Lysergic acid diethylamide (LSD).....................                 35
Marihuana............................................             21,000
Mescaline............................................                 25
Methaqualone.........................................                 10
Methcathinone........................................                 25
Methyldesorphine.....................................                  2
Methyldihydromorphine................................                  2
Morphine Methylbromide...............................                  5
Morphine Methylsulfonate.............................                  5
Morphine-N-oxide.....................................                175
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide                    15
 (AKB48).............................................
N-Benzylpiperazine...................................                 25
N,N-Dimethylamphetamine..............................                 25
N-Ethyl-1-phenylcyclohexylamine......................                  5
N-Ethylamphetamine...................................                 24
N-Hydroxy-3,4-methylenedioxyamphetamine..............                 24
Noracymethadol.......................................                  2
Norlevorphanol.......................................                 52
Normethadone.........................................                  2
Normorphine..........................................                 18
Para-fluorofentanyl..................................                  2
Parahexyl............................................                  5
Phenomorphan.........................................                  2
Pholcodine...........................................                  2
Properidine..........................................                  2
Psilocybin...........................................                 30
Psilocyn.............................................                 30
Tetrahydrocannabinols................................            491,000
Thiofentanyl.........................................                  2
Tilidine.............................................                 10
Trimeperidine........................................                  2
------------------------------------------------------------------------


[[Page 55102]]


------------------------------------------------------------------------
                                                        Established 2014
               Basic Class--Schedule II                  Quotas (grams)
------------------------------------------------------------------------
1-Phenylcyclohexylamine..............................                  3
1-Piperdinocyclohexanecarbonitrile (PCC).............                  3
4-Anilino-N-phenethyl-4-piperidine (ANPP)............          2,687,500
Alfentanil...........................................             17,625
Alphaprodine.........................................                  3
Amobarbital..........................................                  9
Amphetamine (for conversion).........................         18,375,000
Amphetamine (for sale)...............................         49,000,000
Carfentanil..........................................                 19
Cocaine..............................................            240,000
Codeine (for conversion).............................         68,750,000
Codeine (for sale)...................................         46,125,000
Dextropropoxyphene...................................                 19
Dihydrocodeine.......................................            100,750
Diphenoxylate........................................            750,000
Ecgonine.............................................            144,000
Ethylmorphine........................................                  3
Fentanyl.............................................          2,108,750
Glutethimide.........................................                  3
Hydrocodone (for sale)...............................         99,625,000
Hydromorphone........................................          6,750,000
Isomethadone.........................................                  5
Levo-alphacetylmethadol (LAAM).......................                  4
Levomethorphan.......................................                195
Levorphanol..........................................              2,000
Lisdexamfetamine.....................................         23,750,000
Meperidine...........................................          6,250,000
Meperidine Intermediate-A............................                  6
Meperidine Intermediate-B............................                 11
Meperidine Intermediate-C............................                  6
Metazocine...........................................                 19
Methadone (for sale).................................         31,875,000
Methadone Intermediate...............................         38,875,000
Methamphetamine......................................          2,811,375
------------------------------------------------------------------------
[1,250,000 grams of levo-desoxyephedrine for use in a non-controlled,
 non-prescription product; 1,500,000 grams for methamphetamine mostly
 for conversion to a schedule III product; and 61,375 grams for
 methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate......................................         96,750,000
Morphine (for conversion)............................         91,250,000
Morphine (for sale)..................................         62,500,000
Nabilone.............................................             30,375
Noroxymorphone (for conversion)......................         17,500,000
Noroxymorphone (for sale)............................          1,462,500
Opium (powder).......................................            112,500
Opium (tincture).....................................            625,000
Oripavine............................................         22,750,000
Oxycodone (for conversion)...........................          9,250,000
Oxycodone (for sale).................................        149,375,000
Oxymorphone (for conversion).........................         25,000,000
Oxymorphone (for sale)...............................          7,750,000
Pentobarbital........................................         35,000,000
Phenazocine..........................................                  6
Phencyclidine........................................                 19
Phenmetrazine........................................                  3
Phenylacetone........................................         67,000,000
Racemethorphan.......................................                  3
Remifentanil.........................................              3,750
Secobarbital.........................................            215,003
Sufentanil...........................................              6,255
Tapentadol...........................................         17,500,000
Thebaine.............................................        145,000,000
------------------------------------------------------------------------


------------------------------------------------------------------------
                                                         Proposed 2014
            Basic Class--List I Chemicals                    Quotas
------------------------------------------------------------------------
Ephedrine (for conversion)...........................          1,000,000
Ephedrine (for sale).................................          3,000,000
Phenylpropanolamine (for conversion).................         44,800,000
Phenylpropanolamine (for sale).......................          5,300,000
Pseudoephedrine (for conversion).....................              5,000
Pseudoephedrine (for sale)...........................        192,000,000
------------------------------------------------------------------------


[[Page 55103]]

    The Deputy Administrator also establishes aggregate production 
quotas for all other Schedule I and II controlled substances included 
in 21 CFR 1308.11 and 1308.12 at zero. Pursuant to 21 CFR 1303.13 and 
21 CFR 1315.13, upon consideration of the relevant factors, the Deputy 
Administrator may adjust the 2014 aggregate production quotas and 
assessment of annual needs as needed.

    Dated: August 30, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013-21797 Filed 9-6-13; 8:45 am]
BILLING CODE 4410-09-P